220 related articles for article (PubMed ID: 25155552)
1. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Prostate Cancer with Multiple Bone Metastasis with High FGF23 Value Indicated by Intractable Hypocalcemia and Hypophosphatemia].
Nishida S; Shigesawa I; Nagai S; Itoh N; Masumori N
Hinyokika Kiyo; 2021 Jan; 67(1):47-51. PubMed ID: 33535298
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
4. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
5. Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy.
Ramon I; Kleynen P; Valsamis J; Body JJ; Karmali R
Calcif Tissue Int; 2011 Dec; 89(6):442-5. PubMed ID: 21910004
[TBL] [Abstract][Full Text] [Related]
6. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
7. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).
Kinoshita Y; Takashi Y; Ito N; Ikegawa S; Mano H; Ushiku T; Fukayama M; Nangaku M; Fukumoto S
Bone Rep; 2019 Jun; 10():100192. PubMed ID: 30627598
[TBL] [Abstract][Full Text] [Related]
8. Anti-fibroblast growth factor 23 antibody therapy.
Fukumoto S
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
[TBL] [Abstract][Full Text] [Related]
9. FGF23 promotes prostate cancer progression.
Feng S; Wang J; Zhang Y; Creighton CJ; Ittmann M
Oncotarget; 2015 Jul; 6(19):17291-301. PubMed ID: 26019137
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
11. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 and FGFR4 do not mediate renal effects of FGF23.
Liu S; Vierthaler L; Tang W; Zhou J; Quarles LD
J Am Soc Nephrol; 2008 Dec; 19(12):2342-50. PubMed ID: 18753255
[TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
Wu AL; Feng B; Chen MZ; Kolumam G; Zavala-Solorio J; Wyatt SK; Gandham VD; Carano RA; Sonoda J
PLoS One; 2013; 8(2):e57322. PubMed ID: 23451204
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
15. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
16. Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression.
Tuomela J; Härkönen P
Reprod Biol; 2014 Mar; 14(1):16-24. PubMed ID: 24607251
[TBL] [Abstract][Full Text] [Related]
17. [Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].
Ozono K
Clin Calcium; 2010 Jun; 20(6):896-903. PubMed ID: 20513948
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
19. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1.
Sahoo SK; Kushwaha P; Bharti N; Khedgikar V; Trivedi R; Agrawal V; Ahmad N; Zaidi G; Pal L; Ito N; Bhatia E
Bone; 2019 Dec; 129():115055. PubMed ID: 31476437
[TBL] [Abstract][Full Text] [Related]
20. Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells.
Yamazaki M; Ozono K; Okada T; Tachikawa K; Kondou H; Ohata Y; Michigami T
J Cell Biochem; 2010 Dec; 111(5):1210-21. PubMed ID: 20717920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
